GET DAILY SIGNALSIntellia Therapeutics (NTLA) Drops -13% Over 30 Days Following Earnings Miss
Key Takeaways
- Intellia Therapeutics shares declined roughly 13% over the trailing 30 days, falling from a closing price of $13.07 on October 9, 2026, to $11.35 on November 6, 2026.
- The decline was driven largely by third-quarter results reported on November 5, 2026, which showed a wider-than-expected net loss and lower collaboration revenue from Regeneron (REGN).
- Intellia's lead candidate, lonvo-z, remains the central catalyst after the U.S. FDA accepted its biologics license application for hereditary angioedema and granted priority review with a target action date of March 10, 2027.
- Analyst sentiment was mixed during the period: Barclays initiated coverage at Underweight with an $8 price target, while firms including H.C. Wainwright and JonesTrading reiterated Buy ratings.
- The company reported cash, cash equivalents and marketable securities of about $614.8 million as of September 30, 2026, with management guiding that resources should fund operations into at least 2028.
- For additional detail, review Intellia's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see AI-driven trading strategies for stocks like NTLA.
Company Background and Pipeline Focus
Intellia Therapeutics is a clinical-stage genome editing company developing CRISPR/Cas9-based therapies for genetically defined diseases. Headquartered in Cambridge, Massachusetts, the company pursues both in vivo programs, which deliver CRISPR directly inside the body, and ex vivo programs, which edit cells outside the body. Its lead candidate, lonvoguran ziclumeran (lonvo-z), targets hereditary angioedema, while nexiguran ziclumeran (nex-z) targets transthyretin (ATTR) amyloidosis in partnership with Regeneron. Investors follow NTLA closely because lonvo-z could become the first in vivo CRISPR-based therapy to reach the market, positioning Intellia at the forefront of a new class of medicines. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Movement: 30 Days and Quarter
Over the trailing 30 days, NTLA moved from a closing price of $13.07 on October 9, 2026, to $11.35 on November 6, 2026, a decline of approximately 13%. The path was volatile: shares touched an intraday high around $13.94 in late October before retreating sharply after third-quarter results. The quarterly trend has been range-bound, with the stock trading between roughly $10.50 and $13.90 over the past three months and ending modestly lower than its early-August level near $12.00. From what I see, the overall move reflects a mix of company-specific news and broader sector pressures.
Factors Behind the 30-Day Decline
The sharpest move came around third-quarter earnings on November 5, 2026. Intellia reported a net loss of $0.91 per share, wider than consensus estimates, and revenue of $7.2 million that missed expectations and declined 48% year over year on lower collaboration revenue from Regeneron. The stock fell nearly 10% in that session. Earlier in the period, Barclays initiated coverage with an Underweight rating and an $8 price target on October 6, adding to selling pressure. Partly offsetting these headwinds, Intellia named Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, and several analysts reiterated Buy ratings after the earnings print. I checked recent patterns here with Tickeron’s AI Pattern Search Engine for additional context.
Quarterly Drivers and Pipeline Updates
The broader three-month trend was shaped by regulatory momentum and pipeline execution. In September 2026, the FDA accepted the biologics license application for lonvo-z in hereditary angioedema and granted priority review, setting a target action date of March 10, 2027. Intellia also entered a non-dilutive senior secured term loan facility of up to $400 million with OrbiMed to strengthen its balance sheet, and it completed enrollment in the Phase III MAGNITUDE-2 study of nex-z in hereditary ATTR amyloidosis with polyneuropathy. These advances supported periodic rallies, but sector-wide biotechnology volatility and the subsequent earnings miss kept the stock in a broad range over the quarter.
Key Items on the Horizon for Investors
The most important near-term catalyst is the FDA's decision on lonvo-z, expected by March 10, 2027, along with the company's commercial launch readiness for hereditary angioedema. Investors are also likely to monitor enrollment and data updates for the Phase III nex-z programs in ATTR amyloidosis, cash utilization against the stated runway into at least 2028, and any changes in analyst ratings or price targets. Broader factors, including biotechnology sector sentiment, interest-rate expectations, and the performance of the in vivo gene-editing peer group, may continue to influence volatility. I’m watching this closely as the regulatory timeline approaches.
Exploring AI-Driven Trading Approaches
In my own research process, I sometimes turn to automated strategies to test ideas around volatile names like NTLA. Tickeron’s AI Trading Bots offer a range of approaches that incorporate technical signals and market patterns, allowing users to review performance across different timeframes and market conditions. These tools help surface strategies that align with individual risk preferences without replacing fundamental analysis. For those interested in seeing current examples, the platform provides access to a library of bots focused on various tickers and styles.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
NTLA sees MACD Histogram just turned negative
NTLA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 44 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
NTLA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NTLA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NTLA as a result. In 78 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +5.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 206 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 111 of 128 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (3.498). P/E Ratio (-3.398) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. NTLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary, potentially curative therapeutics
Industry Biotechnology
Advertisement